ALEXIS KOZLOWSKI: Open Payments
NPI 1104697036 · ROCKFORD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,246 in 65 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $396 · 2025 $1,246
Food & beverage: $1,246
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $279 |
| GlaxoSmithKline, LLC. | 6 | $138 |
| AstraZeneca Pharmaceuticals LP | 6 | $111 |
| Novo Nordisk Inc | 5 | $100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $94 |
| Esperion Therapeutics, Inc. | 4 | $90 |
| Lilly USA, LLC | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 2 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| Lundbeck LLC | 2 | $48 |
Products named: TRELEGY ELLIPTA, VRAYLAR, JARDIANCE, NEXLETOL, QULIPTA, REXULTI, UBRELVY, Kerendia.
Industry payments across IL — which companies pay providers there.
